Biomarker Monitoring Framework for Safe Tirzepatide Use with Hypothyroidism Establishing baseline biomarkers before starting tirzepatideincluding TSH, free T4, free T3, TPO antibodies, and metabolic panelprovides a clinical anchor for evaluating treatment response
GLP-1 agonists work on leptin and ghrelin, impacting hunger and satiety signaling
Handling and Storage Recommendations Minimize light exposure during handling
[1][7][10] For a deeper comparison of tirzepatide versus semaglutide across multiple factors, the Tirzepatide vs Semaglutide guide covers the evidence in detail
The practical implication: if you have a history of gastroparesis or symptoms suggesting poor gastric emptying (persistent nausea, chronic bloating, vomiting of undigested food hours after eating), this needs to be discussed with your doctor before starting tirzepatide or during any dose increase